Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC PILO versus COREG CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC PILO versus COREG CR.
BETOPTIC PILO vs COREG CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betoptic Pilo is a combination of betaxolol (a cardioselective beta-1 adrenergic receptor antagonist) and pilocarpine (a muscarinic cholinergic agonist). Betaxolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Pilocarpine increases aqueous humor outflow by contracting the ciliary muscle and opening the trabecular meshwork.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
One drop of 0.5% betaxolol and 4% pilocarpine combination ophthalmic solution instilled into the affected eye(s) twice daily.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
None Documented
None Documented
Betaxolol: 16–22 hours (clinical context: allows once-daily dosing for glaucoma). Pilocarpine: 0.5–1.5 hours (rapid elimination, requiring multiple daily dosing).
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Betoptic Pilo (betaxolol and pilocarpine) undergoes both renal and hepatic elimination. Betaxolol is primarily metabolized in the liver (active metabolites) with less than 15% excreted unchanged in urine. Pilocarpine is hydrolyzed in plasma and tissues; its metabolites and a small fraction of unchanged drug are excreted renally. Fecal excretion is negligible.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Category C
Category C
Beta-Blocker
Beta-Blocker